Idiopathic pneumonia syndrome

Hildebrandt GC, Duffner UA, Olkiewicz KM, et al. A critical role for CCR2/ MCP-1 interactions in the development of idiopathic pneumonia syndrome after allogeneic bone marrow transplantation. Blood 2004 103(6) 2417-2426. 

Various authors have discussed the differences in busulfan-induced idiopathic pneumonia syndrome, as a result of either chronic low-dose or short-course high-dose therapy. One group found that chronic low-dose therapy (even at cumulative doses of busulfan of up to 3 g) caused different lung damage from the clinical characteristics, radiological, and pathological features of the idiopathic pneumonia syndrome (6). 

Bilgrami SF, Metersky ML, McNally D, Naqvi BH, Kapur D, Raible D, Bona RD, Edwards RL, Feingold JM, Clive JM, Tutschka PJ. Idiopathic pneumonia syndrome following myeloablative chemotherapy and autologous transplantation. Ann Pharmacother 2001 35(2) 196-201. 

ACE angiotensin-converting enzyme CNS central nervous system COPD chronic obstructive pulmonary disease DPIs dry-powder inhalers EDTA ethylenediamine tetraacetic acid EDA Eood and Drug Administration EEVi forced expiratory volume in 1 second HIV human immunodeficiency virus IPS idiopathic pneumonia syndrome NSAIDs nonsteroidal anti-inflammatory drugs... 

Clark JG, Hansen JA, Hertz MI, et al. Idiopathic pneumonia syndrome after bone marrow transplantation. Am Rev Respir Dis 1993 147 1601-1606. 

Wiedemann HP. Toward an understanding of idiopathic pneumonia syndrome after bone marrow transplantation. Crit Care Med 1999 27 2040-2041. 

Rubio C, Hill ME, Milan S, et al. Idiopathic pneumonia syndrome after high-dose chemotherapy for relapsed Hodgkin s disease. Br J Cancer 1997 75 1044-1048. 

Fukuda T, Hackman RC, Guthrie KA, et al. Risks and outcomes of idiopathic pneumonia syndrome after nonmyeloablative compared to conventional conditioning regimens for allogeneic hematopoietic stem cell transplantation. Blood 2003 102 2777-2785. 

In a model of idiopathic pneumonia syndrome after bone marrow transplantation, iNOS deletional mutant mice (-/-) given donor bone marrow and spleen T cells (BMS) exhibited improved survival compared with matched BMS controls (Yang et al. 2001). Bronchoalveolar lavage fluids obtained on day 7 post bone marrow transplantation from iNOS(-/-) BMS mice contained less tumour necrosis factor-a and interferon-y, indicating that NO... 

Chronic eosinophilic pneumonia Acute eosinophilic pneumonia Lymphangioleiomyomatosis Langerhans cell histiocytosis Idiopathic pneumonia syndrome Inflammatory bowel disease Cryoglobulinemia Primary biliary cirrhosis... 

Figure 1 Timing of the major noninfectious pulmonary complications following blood and marrow transplantation. Abbreviations. BO, bronchiolitis obUterans DAH, diffuse alveolar hemorrhage GVHD, graft versus host disease IPS, idiopathic pneumonia syndrome P edema, pulmonary edema PERDS, periengraftment respiratory distress syndrome phase I, preengraftment period phase II, early postengraftment period phase III, late postengraftment period.

Yanik G, HeUerstedt B, Custer J, et al. Etanercept (Enbrel) administration for idiopathic pneumonia syndrome after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2002 8(7) 395-400. 

Keates-Baleeiro J, Moore P, Koyama T, et al. Incidence and outcome of idiopathic pneumonia syndrome in pediatric stem cell transplant recipients. Bone Marrow Transplant 2006 38(4) 285-289. 

Kantrow SP, Hackman RC, Boeckh M, et al. Idiopathic pneumonia syndrome changing spectrum of lung iniury after marrow transplantation. Transplantation... 

Idiopathic pneumonia syndrome (IPS) is defined as diffuse lung injury occurring after HSC transplantation in the absence of active lower respiratory tract infection even in the presence of non-lobar radio-graphic infiltrates and physiologic changes consistent with pneumonia (Kantrow et al. 1997). Thus,... 

---